Gemcitabine, Ifosfamide and Navelbine for Lung Cancer
Author Information
Author(s): Baldini E, Ardizzoni A, Prochilo T, Cafferata M A, Boni L, Tibaldi C, Neumaier C, Conte P F, Rosso R
Primary Institution: U.O. Oncologia Medica Ospedale S. Chiara, Pisa, Italy
Hypothesis
To evaluate activity and toxicity of a non platinum-based triplet including Gemcitabine, Ifosfamide and Navelbine (GIN) in advanced NSCLC.
Conclusion
The GIN regimen showed promising activity against advanced non-small-cell lung cancer with manageable toxicity.
Supporting Evidence
- The study included 50 patients with advanced non-small-cell lung cancer.
- A total of 200 treatment courses were administered, with a median of 4 courses per patient.
- The response rate was 52%, with one complete response and 24 partial responses.
- Neutropenia grade 3–4 occurred in 47% of the treatment courses.
Takeaway
This study tested a new combination of drugs for lung cancer and found it works well without using platinum-based treatments.
Methodology
Patients with advanced NSCLC received a combination of Gemcitabine, Ifosfamide, and Navelbine every three weeks, and their responses were evaluated.
Potential Biases
Potential bias due to the non-randomized nature of the study.
Limitations
The study had a small sample size and was limited to specific patient characteristics.
Participant Demographics
Median age of participants was 63 years, with 65% having an ECOG performance status of 0 and 79% having stage IV disease.
Statistical Information
Confidence Interval
95% CI: 37.4–66.5%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website